Put companies on watchlist
DocMorris AG
ISIN: CH0042615283
WKN: A0Q6J0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

DocMorris AG · ISIN: CH0042615283 · EQS - Company News (79 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1629693
11 May 2023 07:00AM

DOCM (formerly ROSE)


DocMorris AG / Key word(s): Strategic Company Decision/Miscellaneous
New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)

11.05.2023 / 07:00 CET/CEST


Frauenfeld, 11 May 2023
 

Press release

 

New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)

As of today, the ticker symbol for the shares of DocMorris AG – formerly Zur Rose Group AG – traded on the SIX Swiss Exchange is now "DOCM". ISIN and Valor remain unchanged.

The Annual General Meeting approved the change of name from Zur Rose Group AG to DocMorris AG on 4 May 2023.

 

 

Investors and analyst contact
Dr. Daniel Grigat, Group Head of Investor Relations & Sustainability
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Group Director Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

 

Agenda

17 August 2023 2023 Half-Year Results (11 a.m. CEST: Conference Call/Webcast)
19 October 2023 Q3/2023 Trading Update

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. As Germany's largest online pharmacy, it operates DocMorris, the best-known health platform. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 2,200 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,159 million serving around 10 million active customers in 2022. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 



End of Media Release


Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
Phone: +41 52 724 08 14
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1629693

 
End of News EQS News Service

1629693  11.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1629693&application_name=news&site_id=boersengefluester_html
Visual performance / price development - DocMorris AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.